Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • Internal Medicine • Myeloproliferative Neoplasms • Hematology • Polycythemia Vera
Under which circumstances would you prefer ropeginterferon over hydroxyurea for patients with Polycythemia Vera?
Ropeginterferon is now a preferred therapy for Polycythemia Vera (PV) as per a recent update to the NCCN guidelines.
Answer from: at Academic Institution
The approval of ropeginterferon (Besremi) for the treatment of polycythemia vera (PV) without any restrictions was a welcome event for PV patients and their physicians. First, because this drug selectively targets the JAK2-mutated hematopoietic stem cell (HSC) responsible for PV and can produce comp...
Sign in or Register to read more